A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (clinicaltrials.gov) - Oct 14, 2026 - P3 | N=530 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Apr 2028 ➔ Aug 2027
Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|